CIP
PACB icon

Convergence Investment Partners’s Pacific Biosciences PACB Stock Holding History

Convergence Investment Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,371
Closed -$212K – 273
2021
Q1 		$212K Sell
6,371
-6,027
-49% -$211K 0.1% 194
2020
Q4 		$322K Buy
+12,398
New +$211K 0.16% 131

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Convergence Investment Partners's PACB Position: Q2 2021 in Review

Convergence Investment Partners sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 6,371 shares — an estimated $212K sold.

Convergence Investment Partners first reported a position in PACB in Q4 2020 and held it in 2 quarters. The position peaked at $322K in Q4 2020. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

  • Convergence Investment Partners reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
  • Convergence Investment Partners sold 6,371 Pacific Biosciences shares in Q2 2021, an estimated $212K.
  • Convergence Investment Partners first reported a position in Pacific Biosciences in Q4 2020 and held it in 2 quarters.
  • Convergence Investment Partners's Pacific Biosciences position peaked at $322K in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on Convergence Investment Partners's 13F filing for Q2 2021, filed 19 Jul 2021.